Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

FALCON-Studie testet Maßnahmen zur Reduzierung von Infektionen an Operationsstellen (FALCON)

11. November 2026 aktualisiert von: University of Birmingham

Pragmatische, multizentrische, randomisierte, kontrollierte Studientestmaßnahmen zur Reduzierung von postoperativen Wundinfektionen in Ländern mit niedrigem und mittlerem Einkommen

FALCON is a Pragmatic multi-centre trial testing measures to reduce superficial or deep skin infection following abdominal surgery in low and middle income countries. The trial will recruit patients undergoing abdominal surgery. Recruited participants will be randomly assigned to four arms to receive different combinations of skin preparation and sutures for would closure:

A. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and non-coated suture for wound closure; B. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and triclosan coated suture for wound closure; C. In this arm surgeon will use for operation 10% aqueous povidone-iodine for skin cleansing and non-coated suture for wound closure; D. In this arm surgeon will use 10% aqueous povidone-iodine for skin cleansing and triclosan-coated suture.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

FALCON is a pragmatic, blinded (patient and outcome assessor), 2x2 factorial, stratified, multi-centre randomised controlled trial, with an internal pilot, to evaluate measures to reduce Surgical Site Infection (SSI) rates in patients undergoing surgery with an abdominal incision.

Surgical site infection (SSI) represents a major burden for patients, doctors, and health systems across all settings. SSI is the commonest postoperative complication worldwide and the commonest healthcare-associated infection in low and middle income countries (LMICs). SSIs cause pain, discomfort, disability, and increase the time taken to return to work (3). SSIs increase healthcare costs in all health settings. Whilst there is no direct data on the costs of SSI in LMICs, within the UK National Health Service, SSIs cost approximately £3500 per patient and £700 million per year in total. The impact of increased healthcare costs on patients, communities, and providers can be major in LMICs where personal income is low and patients may be required to pay for their own treatment. SSI has also been associated with one-third of postoperative deaths and accounts for 8% of all deaths caused by a hospital acquired infection.

Strata in FALCON trial are defined according to the anticipated category of wound contamination: (1) clean-contaminated and (2) contaminated/dirty. Eligible patients will be randomised at the level of the individual in a 1:1:1:1 ratio between:

A. 2% alcoholic chlorhexidine and non-coated suture B. 2% alcoholic chlorhexidine and triclosan-coated suture C. 10% aqueous povidone-iodine and non-coated suture D. 10% aqueous povidone-iodine and triclosan-coated suture.

Participant will be recruited from hospitals in Low and Middle Income Countries (LMICs). Participants who is undergoing abdominal surgery with an anticipated clean-contaminated, contaminated or dirty surgical wound will be selected to enter the trial.

The 6 month internal pilot will assess the feasibility of recruitment, compliance with treatment allocation and patient retention and follow-up rates. The main RCT will recruit 5480 participants.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

5788

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Cotonou, Benin
        • University of Abomey Calavi
      • Tamale, Ghana
        • Tamale Teaching Hospital, Tamale
      • Ludhiana, Indien
        • Christian Medical College and Hospital Ludhiana
      • Veracruz, Mexiko
        • Hospital Espanol Veracruz
      • Lagos, Nigeria
        • Lagos University Teaching Hospital
      • Kigali, Ruanda
        • University Teaching Hospital of Kigali (Hub), Kigali
      • Johannesburg, Südafrika
        • University of the Witwatersrand

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

1 Sekunde bis 100 Jahre (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Patients with at least one abdominal incision that is ≥5cm (open or laparoscopic extraction site), with an anticipated clean-contaminated, contaminated or dirty surgical wound.
  • Patients undergoing emergency (surgery on an unplanned admission) or elective (surgery on a planned admission) operations.
  • Any operative indication, including trauma surgery.
  • Patient able and willing to provide written informed consent (signature or a fingerprint).
  • Paediatric and adult patients. This criteria is made country-specific. Each country decides the lower age limit for the trial. This is dependent on country-specific regulatory approvals. Age eligibility will vary by country.

Exclusion Criteria:

  • Patients with a documented or suspected allergy to iodine, shellfish, or chlorhexidine skin preparation solution.
  • Patient unable to complete post-operative follow-up (i.e. will not be contactable after discharge).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Fakultätszuweisung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: 2%chlorhexidine + non-coated suture

2%alcoholic chlorhexidine + non-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.

Interventions:

2% alcoholic chlorhexidine non-coated suture

Aktiver Komparator: 2%chlorhexidine + coated suture

2%alcoholic chlorhexidine + triclosan-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.

Interventions:

2% alcoholic chlorhexidine triclosan coated suture

Aktiver Komparator: 10% povidone-iodine + non-coated suture

10% povidone-iodine and non-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.

Interventions:

10% povidone-iodine non-coated suture non-coated suture

Aktiver Komparator: 10%povidone-iodine + coated suture

10%povidone-iodine/triclosan-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.

Interventions:

10% povidone-iodine triclosan coated suture

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Surgical site infection (SSI)
Zeitfenster: At 30-days post-surgery

Deep incisional or superficial incisional SSI which must occur within 30 days of the index operation. The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision. Patient must at least have one of the following: (1) purulent discharge from wound; (2) organisms detected from wound swab; (3) Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; systemic fever (>38°C); (4) Diagnosis of SSI by a clinician or on imaging.

At 30-days post-surgery

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Physiological parameter - SSI at discharge from hospital
Zeitfenster: Within 30-days post surgery from index operation

Deep incisional or superficial incisional SSI. The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision and the patient must have one of the following: (1) purulent discharge from wound; (2) organisms detected from wound swab; (3) Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; systemic fever (>38°C); (4) Diagnosis of SSI by a clinician or on imaging.

Within 30-days post surgery from index operation
Mortality - patient mortality status
Zeitfenster: Within 30-days post surgery from index operation

Mortality within 30-days post surgery

Within 30-days post surgery from index operation
Physiological parameter - Unplanned wound opening
Zeitfenster: Within 30-days post surgery from index operation

Whether an unplanned wound opening has occurred at abdominal surgical site within 30-days post surgery, spontaneously opened or by clinician

Within 30-days post surgery from index operation
Re-operation for SSI
Zeitfenster: Within 30-days post surgery from index operation

Re-operation for SSI within 30-days post surgery

Within 30-days post surgery from index operation
Length of hospital stay for index admission
Zeitfenster: Within 30-days post surgery from index operation

Length of hospital stay for index admission will be collected and will measure time from surgery to time of discharge.

Within 30-days post surgery from index operation
Participant's Readmission
Zeitfenster: Within 30-days post surgery from index operation

Whether patient readmitted within 30-days post surgery

Within 30-days post surgery from index operation
Questionnaire - return to normal activities
Zeitfenster: Within 30-days post surgery from index operation

Return to normal activities (e.g. work, school, or family duties) ascertained by trial specific questionnaire

Within 30-days post surgery from index operation
Resistance of organisms
Zeitfenster: Within 30-days post surgery from index operation

Resistance of organisms detected from wound swabs to prophylactic antibiotics administered within 1 hour of incision

Within 30-days post surgery from index operation
Questionnaire - Health resource usage
Zeitfenster: Within 30-days post surgery. Health resource usage will only be collected for adult patients (aged 18 and above) at pre-selected centres. This will include costs of post-operative visits to various healthcare professionals.

Health resource usage within 30-days post surgery ascertained by trial specific questionnaire

Within 30-days post surgery. Health resource usage will only be collected for adult patients (aged 18 and above) at pre-selected centres. This will include costs of post-operative visits to various healthcare professionals.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Dion Morton, University of Birmingham

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

29. November 2018

Primärer Abschluss (Tatsächlich)

7. September 2020

Studienabschluss (Tatsächlich)

31. Oktober 2020

Studienanmeldedaten

Zuerst eingereicht

23. August 2018

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. Oktober 2018

Zuerst gepostet (Tatsächlich)

9. Oktober 2018

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. September 2019

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • RG_17-126

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .